APsystems Unveils Full-Scope AI-Driven Solar & Storage Solutions at SNEC 2025
SHANGHAI, June 12, 2025 /PRNewswire/ -- APsystems made a strong impression at the 18th SNEC PV Power & Energy Storage Expo, held at the National Exhibition and Convention Center in Shanghai. With more than 15 years of disruptive technological innovation, the company introduced its latest advancements in solar and storage technologies, highlighting new products and showcasing the impact of AI integration on energy management.
Leading with Innovation: New Product LaunchesAPsystems is introducing the QS2, a brand new single-phase quad microinverter with an impressive 2200W output and support for four high-power PV modules via independent MPPT channels. Designed for safety and efficiency, its module-level architecture keeps DC voltage below 60V during operation, effectively minimizing high-voltage risks. The upgraded Zigbee module enhances communication speed and stability, while the QS2's compatibility with other APsystems single-phase models like the DS3 and QS1 makes system design more flexible.
Also introduced was the AHS series Solar Battery Hybrid Controller, designed for off-grid and backup power scenarios. Supporting 12V/24V/48V lead-acid and lithium batteries, the flagship AHS-6.3 delivers a 6300VA pure sine wave output with 99.9% MPPT efficiency and seamless 5ms UPS switching. With IP43 cooling and real-time app monitoring, it's built for reliability in both home and telecom applications.
Versatile Solar + Storage Solutions for Every NeedAPsystems highlighted its complete lineup of distributed energy solutions across micro, residential, and commercial applications. The EZ1/EZHI series empower DIY users with microgrid capabilities and energy independence. For residential settings, 20A microinverters and ELS/ELT storage options provide flexible options. In the C&I space, the QT2 three-phase microinverters and Ocean series storage systems are designed for cost efficiency and scalable performance.
Smarter Energy with AI IntegrationA major focus this year was APsystems' AI-driven enhancements. The new BESS AI model uses deep learning to forecast energy generation and consumption based on historical data and local energy prices. This enables automatic, personalized charge/discharge schedules for balcony and residential storage systems—delivering smarter, more efficient energy use.
APsystems also unveiled APbot, a smart support assistant built on advanced AI architecture using private LLM deployment and RAG technology. Designed to improve customer interaction, APbot delivers fast, accurate responses using semantic search and knowledge-based reasoning, all while being easily adaptable for global compliance needs.
The AP Designer tool also received an AI boost. Now featuring image recognition, real-time simulation, and 3D modeling, it streamlines PV design by analyzing rooftops, trees, and shading. With online design capabilities and automatic report generation, it simplifies everything from planning to budget forecasting.
Thank you to everyone who visited our booth at SNEC 2025. We appreciate your interest and look forward to connecting again next time!
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/apsystems-unveils-full-scope-ai-driven-solar--storage-solutions-at-snec-2025-302479709.html
SOURCE Altenergy Power System Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Norfolk Southern board of directors elects Richard Anderson as chair
ATLANTA, June 12, 2025 /PRNewswire/ -- Norfolk Southern Corporation's (NYSE: NSC) Board of Directors has unanimously appointed Richard H. Anderson, the former CEO and Executive Chairman of Delta Air Lines, President of Optum Health, CEO of Northwest Airlines, and most recently President and CEO of Amtrak, as the independent chair of the board, effective immediately. Anderson has served on Norfolk Southern's board since May of 2024. Anderson will also serve as chair of the Executive Committee and the Strategy & Planning Committee. In addition, Jack Huffard, co-founder and director of Tenable Holdings, Inc., has been appointed as chair of the Compensation and Talent Management Committee. These appointments are also effective immediately. The board has agreed to reduce its size to 12 members and remaining committee chairs will continue in their existing positions. "Since the very beginning of his time on our board, Richard has contributed deep, experience-based business insight and a collaborative style that has helped drive cohesion among the newly-constituted Board," said Mark George, President and CEO of Norfolk Southern. "I look forward to working with him in this new capacity as we continue to build on Norfolk Southern's strong momentum, advance our strategic priorities, and deliver long-term value for our shareholders, customers, and employees." Anderson said, "During my year on the board, I've seen firsthand how the Norfolk Southern team has propelled the company forward — delivering strong performance for stakeholders and becoming an even safer, more efficient railroad. Alongside the management team and dedicated employees, the board remains focused on delivering value for all our stakeholders." More about Richard H. Anderson is available at About Norfolk Southern Since 1827, Norfolk Southern Corporation (NYSE: NSC) and its predecessor companies have safely moved the goods and materials that drive the U.S. economy. Today, it operates a 22-state freight transportation network. Committed to furthering sustainability, Norfolk Southern helps its customers avoid approximately 15 million tons of yearly carbon emissions by shipping via rail. Its dedicated team members deliver approximately 7 million carloads annually, from agriculture to consumer goods. Norfolk Southern also has the most extensive intermodal network in the eastern U.S. It serves a majority of the country's population and manufacturing base, with connections to every major container port on the Atlantic coast as well as major ports across the Gulf Coast and Great Lakes. Learn more by visiting View original content to download multimedia: SOURCE Norfolk Southern Corporation
Yahoo
an hour ago
- Yahoo
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations. Details are listed below： Title: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)Abstract #：306-OR Presentation Form: Oral presentationTime: 2025 June 23, 14:15 PM – 14:30 PM（CST）Presenter: Dr. Lei Qian, Innovent Biologics Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical studyAbstract #：1886-LBPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Dr. Decheng Ren, Innovent Biologics Title: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat AccumulationAbstract #：777-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Hong, Peking University Third Hospital Title: Effect of Mazdutide on MASH Fibrosis – Targeting the Liver-Gut Axis and MicrobiomeAbstract #：1616-P Presentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Professor Ling Li, Zhongda Hospital Affiliated to Southeast University Title: Mazdutide, a Dual GLP-1R/GCGRR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Metabolism and Inhibiting Hepatic Purine MetabolismAbstract #：775-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Professor Hongwei Jiang, The First Affiliated Hospital of Henan University of Science and Technology Dr. Lei Qian, Vice President of Clinical Development of Innovent, stated, "We are honored to orally present the results of mazdutide's first Phase 3 clinical trial in T2D (DREAMS-1) at the ADA Scientific Sessions. We are also delighted to see mazdutide's mechanism exploration studies featured extensively at the conference. The growing body of medical evidence will further validate mazdutide's differentiated profile as a next-generation GCG/GLP-1 dual receptor agonist, in particularly in liver fat and serum urine reduction. Moreover, in the field of cardiovascular and metabolic diseases, Innovent is dedicated to developing next-generation innovative therapies, including IBI3030（PCSK9-GGG）with novel modality and MoA, to meaningfully improve outcomes for more patients worldwide." About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Currently, Mazdutide has two NDAs accepted for review by NMPA, including: Long-term weight management in adults with obesity or overweight. Glycemic control in adults with type 2 diabetes (T2D). Mazdutide is currently being evaluated in six Phase 3 clinical studies, including: GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity. GLORY-3: A Phase 3 trial comparing Mazdutide and Semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial in treatment-naïve Chinese participants with T2D. DREAMS-2: A Phase 3 trial comparing Mazdutide and Dulaglutide in Chinese T2D participants with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 trial comparing Mazdutide and Semaglutide in Chinese participants with T2D and obesity. Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and others are currently ongoing. In addition, several new clinical studies of mazdutide are planned, including: A Phase 3 trial in adolescents with obesity. New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Peak Energy expands Japan footprint with acquisition of 11 MW of high-voltage solar assets
Solar projects to come online by 2027 and enable corporates in Japan to decarbonize operations and save costs. SINGAPORE and TOKYO, June 13, 2025 /PRNewswire/ -- Peak Energy, a pan-Asian renewable energy developer and Independent Power Producer (IPP), has acquired 11 MW of ready-to-build (RTB) high-voltage solar projects across Japan. Located in four different regions of Japan (Chubu, Chugoku, Hokkaido and Kansai), the projects are scheduled for completion in 2027 and are expected to generate more than 13 GWh of clean electricity each year for several decades, thereby avoiding nearly 6,000 tonnes of CO₂ emissions annually, equivalent to removing around 2,000 cars from the road. The electricity produced from these sites will be sold to corporates through long-term power purchase agreements (PPAs), at fixed prices, allowing customers to make immediate savings on their electricity bills and to shield themselves from fluctuations in electricity tariffs for 20+ years. This transaction also marks another milestone in Peak Energy's rapid growth in Japan, where the company already co-owns a 28 MW plant in Kyushu and is actively expanding activities across a range of energy services, including onsite solar, offsite solar and collocated solar + battery energy storage systems (BESS). Across the Asia-Pacific region, Peak now owns over 200 MW of solar projects in operation or under construction, along with 298 MWh of battery energy storage capacity in operation or under construction. "This acquisition reinforces our long-term commitment to Japan," said Gavin Adda, CEO of Peak Energy. "Combined with our broader pipeline of high-voltage assets, it will support our mission to deliver clean, affordable and reliable energy solutions to businesses nationwide." "Given how slowly new supply of large-scale solar capacity is coming on stream in our country, we are excited that we will be able to provide our corporate customers with clean energy within the next couple of years," added Eiji Sato, Country President of Peak Energy in Japan. About Peak Energy Headquartered in Singapore, Peak Energy develops, owns, and operates renewable energy assets across Asia. Peak Energy delivers clean, affordable, and reliable power solutions to corporate customers through a diverse range of business models, including utility-scale solar, off-site and on-site corporate PPAs, and battery storage. Peak currently owns over 200 MW of operating assets across the region, including 28 MW in Japan. Peak Energy is wholly owned by Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, with approximately USD 73 billion in assets under management. Media ContactPeak Energymedia@ Peak Energy Japan View original content to download multimedia: SOURCE Peak Energy
